Description
In the Multi-Peptide ELISA, we have combined the major advantages of Western Blot, which is the use of pure proteins or antigens, with the quantitative nature of the ELISA assay.
We also measure antibodies against antigens known for their involvement with Lyme disease, including antibodies against the Borrelia subspecies Sensu stricto, Afzelii, Garinii and Miyamotoi, as well as the co-infections Babesia, Bartonella and Ehrlichia. In this patented methodology, we measure IgG and IgM antibodies not only against a mixture of Borrelia antigens but also separately against proteins or peptides of different molecular sizes, such as OspA, OspB, OspC, OspE, LFA, VMP, DbpA and more.
We use both Borrelia antigens grown in culture and the various proteins expressed in vivo, enabling us to improve the accuracy of our determinations. It is vital to correctly determine as early as possible whether someone is developing Lyme disease or something else. False positive test results could lead to years of incorrect treatment and unnecessary medications with their side effects, while false negative results could lead to Lyme arthritis, neuroborreliosis, and years or even a lifetime of suffering.
The combination of the gold standard ELISA method with the 4 core principles of lab testing (antigen purity, optimization, validation, duplicate testing) has resulted in an accurate and reliable method for detecting Lyme disease.
Methodology
-
When should I use
Consider this panel for detecting active and chronic Lyme disease, especially in patients with symptoms like fever, swollen glands, joint pain, and neurological issues.
If the patient is taking steroids, immunosuppressant medications or other medications that may suppress antibodies please check if it is appropriate for them to test.
Other Details
Other tests to consider
MS2015 B. Burgorferi IgG and IgM by ELISA
MS2016 B. Burgorferi IgG and IgM by Western Blot
MS2018 Immunoserology of Lyme Panel B
